Physician profile
David R Simon
NPI 1922089135
$1,138.59
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $328 · 2021: $104 · 2022: $36.18.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $265.33 | 2019-2020 | |
| Novo Nordisk INC | $180.97 | 2019-2021 | |
| Glaxosmithkline, LLC. | $145.75 | 2019-2020 | |
| Pfizer INC. | $128.74 | 2019-2022 | |
| Lilly USA, LLC | $104.99 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.12 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $81.56 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $51.22 | 2019-2020 | |
| Amarin Pharma, INC. | $27.17 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $21.08 | 2021 | |
| Gilead Sciences, INC. | $19.21 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.45 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.